Search

Compugen Ltd

Uždarymo kaina

2.54 -3.05

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.52

Max

2.63

Pagrindiniai rodikliai

By Trading Economics

Pajamos

663K

-7M

Pardavimai

426K

2.6M

P/E

Sektoriaus vid.

6.737

56.659

Pelnas, tenkantis vienai akcijai

-0.07

Pelno marža

-269.254

Darbuotojai

75

EBITDA

665K

-7M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+95.31% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

17M

242M

Ankstesnė atidarymo kaina

5.59

Ankstesnė uždarymo kaina

2.54

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-03 23:56; UTC

C.H. Robinson Worldwide shares are lower in after-market trading, despite a broader market rally amid reduced interest rate hike expectations.

2026-09-03 23:56; UTC

News

Missouri American Water acquired Neosho's water systems for $34.5 million, adding 5,400 customers. Shares of American Water Works traded higher in after-market hours.

2026-09-03 23:56; UTC

SiTime Corp shares are lower in after-market hours, continuing a decline that began earlier, despite gains in major indices.

2026-09-03 23:56; UTC

Elme Communities shares traded roughly flat in after-market hours. Broader market trends reflect gains in major averages amid reduced interest rate hike expectations.

2026-09-03 23:56; UTC

News
Correlated Moves

Paychex receives a buy rating on strong revenue growth and strategic AI integration. After-market trading has shown little change since Thursday's close.

2026-09-03 23:56; UTC

News

Jefferies initiated coverage on Nexgen Energy with a Buy rating and a C$21 price target. Shares moved higher in after-market hours.

2026-09-03 23:56; UTC

Tapestry Inc. shares rose slightly in after-market trading, reflecting broader market gains amid reduced interest rate hike expectations. They remain below their 20-day moving average.

2026-09-03 23:56; UTC

Loews Corp shares are higher in after-market hours, reflecting broader market gains amid reduced interest rate hike expectations.

2026-09-03 23:56; UTC

Union Pacific Corp shares are higher in after-market trading, following gains in major indices amid reduced interest rate hike expectations, according to CME Group's FedWatch Tool.

2026-09-03 23:56; UTC

Sportsman's Warehouse shares advanced in after-market trading, reflecting broader market gains amid reduced expectations for an interest rate hike.

2026-09-03 23:56; UTC

CRISPR Therapeutics AG shares are lower in after-hours trading, continuing a decline since Thursday's close, despite broader market gains. No specific news was identified.

2026-09-03 23:56; UTC

General Motors traded roughly flat after-market hours amid strong market momentum driven by reduced interest rate hike expectations, according to CME Group's FedWatch Tool.

2026-09-03 23:56; UTC

Wingstop Inc shares are trading higher in after-market hours, supported by strong gains in major indices amid reduced interest rate hike expectations, according to CME Group.

2026-09-03 23:51; UTC

Exelon Corp shares are lower in after-market hours, diverging from broader market gains amid anticipation of upcoming employment data. No specific news was identified.

2026-09-03 23:51; UTC

Japan's Household Spending Falls 3.6% YoY in July, Marking Eighth Straight Month of Decline Amid Economic Uncertainty

2026-09-03 23:51; UTC

Japan's Household Spending MoM for July rises 0.5%, falling short of 2.6% expectations, raising concerns over consumer behavior amid a year-on-year decline of 3.6%.

2026-09-03 23:51; UTC

Canada's Ivey PMI forecasted to rise to 56.2 in August, signaling cautious optimism amid mixed business confidence trends and regional recovery signals.

2026-09-03 23:51; UTC

Iovance Biotherapeutics Inc shares are higher in after-market trading, maintaining a position above its 20-day moving average amid broader market gains.

2026-09-03 23:51; UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit over misleading statements about its Phase III Fianlimab-Libtayo Study, with shares trading lower in after-market hours.

2026-09-03 23:51; UTC

News
Social Media

Dutch Bros Inc filed a mixed securities shelf registration, enabling potential issuance of various securities. Shares are trading higher in after-market hours.

2026-09-03 23:51; UTC

Yelp Inc shares are higher in after-market trading, following gains in the broader market. No specific company news was identified to explain the movement.

2026-09-03 23:51; UTC

News
Social Media

Tesla Inc. shares are lower in after-market trading following the invite-only launch event for its Cybercab in Austin, as details remain restricted.

2026-09-03 23:51; UTC

Shake Shack Inc shares are lower in after-market hours, continuing a downward trend below the 20-day moving average and nearing the one-month range low.

2026-09-03 23:46; UTC

Hilton Worldwide Holdings Inc shares are trading higher in after-market hours, supported by gains in major indices amid anticipation of Friday's employment report.

2026-09-03 23:46; UTC

Correlated Moves

Kimco Realty Corp shares are lower in after-market hours, reflecting a decline since Thursday's close. Broader market trends also show weakness.

2026-09-03 23:46; UTC

News

Weyerhaeuser Co remains about 4.95% below its 20-day moving average. Shares were roughly flat in after-market hours following a price target cut to $28.

2026-09-03 23:46; UTC

FedEx Corp shares are lower in after-market trading, reflecting a decline from Thursday's close. The stock showed initial strength before pulling back.

2026-09-03 23:46; UTC

Correlated Moves

AMETEK Inc. shares declined in after-market trading, reflecting broader small-cap market trends amid significant gains in major indices earlier in the session.

2026-09-03 23:46; UTC

Correlated Moves

Box Inc shares are lower in after-market hours following significant volatility. The decline may be linked to a drop in Asana Inc's stock.

2026-09-03 23:46; UTC

Marcus & Millichap shares are lower in after-market trading, despite broader market gains. No specific news was identified to explain the decline.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

95.31% į viršų

12 mėnesių prognozė

Vidutinis 5 USD  95.31%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat